Skip to content
DataLookout
Menu

NCT06589596

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 31 versions: 28 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Sep 30, 2027 to Aug 31, 2028 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 42 words
    • Enrollment increased: 525 → 695 participants
    • Interventions modified
    • Trial arms changed: 4 → 6
    • Secondary endpoints: details revised at 3 of 14 entries
    • Study description expanded, about 224 words
  2. Minor Trial sites expanded: 98 → 101 locationsv30
  3. Minor Study sites: 96 to 98v29
  4. Minor Trial sites expanded: 92 → 96 locationsv28
  5. Minor Trial sites expanded: 87 → 92 locationsv27
  6. Minor Trial sites expanded: 82 → 87 locationsv26
  7. Minor Study sites: 80 to 82v25
  8. Notable Enrollment increased: 244 → 525 participantsv24 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Primary and study completion moved earlier from Jan 2029 to Sep 30, 2027
    • Start date: Oct 11, 2024 to Jan 10, 2025
    • Trial sites expanded: 62 → 80 locations
    • Study description expanded, about 1 word
  9. Minor Study sites: 59 to 62v23
  10. Minor Study sites: 47 to 59v22
  11. Minor Site details revised at 1 of 47 sitesv21
  12. Minor Study sites: 45 to 47v20
  13. Minor Study sites: 44 to 45v19
  14. Notable Lead sponsor: BeiGene to BeOne Medicinesv17 Show 5 more changesShow less
    • Primary and study completion dates: Jun 2027 to Jan 2029
    • Eligibility criteria expanded, about 29 words
    • Enrollment target: 237 to 244
    • Study sites: 41 to 44
    • Study description expanded, about 36 words
  15. Minor Study sites: 36 to 41v16
  16. Minor Study sites: 45 to 36v15
  17. Notable Enrollment target: 92 to 237v12 Show 9 more changesShow less
    • Primary and study completion dates: Nov 2026 to Jun 2027
    • Eligibility criteria expanded, about 73 words
    • Primary endpoints: 5 to 6
    • Interventions: BGB-58067 (Drug) to BG-89894 (Drug), BGB-58067 (Drug), Standard of Care Therapy (Drug)
    • Secondary endpoints revised (14)
    • Study description expanded, about 11 words
    • Study sites revised (45)
    • Study title expanded, about 10 words
    • Study arms: 2 to 4
  18. Minor Site details revised at 3 of 45 sitesv11
  19. Minor Study sites: 37 to 45v10
  20. Minor Study sites: 32 to 37v9
  21. Minor Site details revised at 3 of 32 sitesv8
  22. Minor Study sites: 30 to 32v7
  23. Minor Site details revised at 4 of 30 sitesv6
  24. Minor Site details revised at 1 of 30 sitesv5
  25. Minor Site details revised at 6 of 30 sitesv4
  26. Minor Study sites: 1 to 30v3
  27. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria revised
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 2024 to Oct 11, 2024
    v2
  28. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1a: Number of Participants with Adverse Events and Serious Adverse Events
Timeframe: From first dose of the study drug(s) to 30 days after the last dose or initiation of a new anticancer therapy, whichever occurs first (approximately 13 months)
Phase 1a: Number of Participants with Adverse Events that meet Dose-Limiting Toxicity (DLT) criteria
Timeframe: Approximately 1 month
Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-58067 alone, in combination with BG-89894, and in combination with standard of care therapy
Timeframe: Approximately 1 month
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BGB-58067 alone, in combination with BG-89894, and in combination with standard of care therapy
Timeframe: Approximately 13 months
Phase 1b: Recommended Phase 2 Dose (RP2D) of BGB-58067 alone and in combination with standard of care therapy or novel anticancer therapies
Timeframe: Approximately 2 years
Phase 1b: Objective Response Rate (ORR)
Timeframe: Approximately 2 years

Secondary (14)

Phase 1a: Objective Response Rate (ORR)
Phase 1a and 1b: Maximum observed plasma concentration (Cmax) of BGB-58067
Phase 1a and 1b: Minimum observed plasma concentration (Cmin) of BGB-58067
Phase 1a and 1b: Time to reach maximum observed plasma concentration (Tmax) of BGB-58067
Phase 1a and 1b: Apparent oral clearance (CL/F) for BGB-58067
Show 9 moreShow less
Phase 1a and 1b: Half-life (t1/2) of BGB-58067
Phase 1a and 1b: Area under the concentration-time curve (AUC) of BGB-58067
Phase 1a and 1b: Apparent volume of distribution (Vz/F) for BGB-58067
Phase 1a and 1b: Accumulation ratio (AR) for BGB-58067
Phase 1a and 1b: Plasma concentrations of BGB-58067
Phase 1a and 1b: Duration of Response (DOR)
Phase 1a and 1b: Disease Control Rate (DCR)
Phase 1b: Number of Participants with AEs and SAEs
Phase 1b: Progression-Free Survival (PFS)

Arms and interventions

Phase 1a: BGB-58067 Monotherapy Dose Escalation and Safety ExpansionExperimental

Sequential cohorts of increasing dose levels of BGB-58067 as monotherapy will be evaluated.

Phase 1a: BGB-58067 + BG-89894 Combination Therapy Dose EscalationExperimental

Sequential cohorts of increasing dose levels of BGB-58067 in combination with BG-89894 will be evaluated. Enrollment in this combination has been discontinued.

Phase 1a: BGB-58067 + Standard of Care Combination Therapy Dose EscalationExperimental

Sequential cohorts of increasing dose levels of BGB-58067 in combination with standard of care therapy will be evaluated.

Phase 1b: BGB-58067 Monotherapy Dose Expansion and OptimizationExperimental

Recommended Dose(s) for Expansion (RDFE\[s\]) of BGB-58067 alone will be evaluated for selected indications and regimen(s) based on emerging data.

Phase 1b: BGB-58067 + Standard of Care Combination Therapy Dose Expansion and OptimizationExperimental

RDFE(s) of BGB-58067 in combination with standard of care therapy will be evaluated for selected indications and regimen(s) based on emerging data.

Phase 1b: BGB-58067 + Novel Anticancer Therapies Combination Therapy Dose Expansion and OptimizationExperimental

RDFE(s) of BGB-58067 in combination with novel anticancer therapies will be evaluated for selected indications and regimen(s) based on emerging data.

Drugs: BGB-58067, BG-89894, Standard of Care Therapy, RAS(ON) Inhibitors

Sites

101 sites in 11 countries

China 47, United States 12, Brazil 10, South Korea 6, Australia 5, France 5, Malaysia 5, Thailand 5, Spain 4, Denmark 1, Moldova 1